![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
liveonearthA new study suggests that these fourteen drugs are being used off label without sufficient evidence to assure that the use is effective. Six of the fourteen are being used for bipolar disorder, which suggests how hard it is to treat. The off label uses are in parentheses:
--quetiapine (bipolar maintenance) --usu used for schizophrenia
--warfarin (hypertensive heart disease)
--escitalopram (bipolar disorder)
--risperidone (bipolar maintenance)
--montelukast (chronic obstructive pulmonary disease)
--bupropion (bipolar disorder)
--sertraline (bipolar disorder)
--venlafaxine (bipolar disorder)
--celecoxib (fibromatosis)
--lisinopril (coronary artery disease)
--duloxetine (anxiety disorder)
--trazodone (sleep disturbance)
--olanzapine (depression)
--epoetin alfa (anemia of chronic disease)
SOURCES:
http://www.medscape.com/viewarticle/584215?src=mpnews&spon=34&uac=89474MT
(login may be required for medscape, costs nothing)
Pharmacotherapy. 2008;28:1443–1452.
This study was performed by members of the Chicago-Area DEcIDE Center under contract to the Agency for Healthcare Research and Quality (AHRQ) of the US Department of Health and Human Services, Rockville, Maryland. No statement may be construed as the official position of the AHRQ.
Dr. Stafford has received no funding directly relevant to this topic. He has received grant funding from Bayer for research on aspirin use, some of it off-label; Procter and Gamble for bone health research; Toyo Shinyaku for research on an antioxidant dietary supplement; Wako for research testing office-based laboratory equipment; and GlaxoSmithKline for research on calcium supplement use.
Dr. DeVane is a consultant for Janssen Pharmaceuticals, Eli Lilly, Wyeth, Theracos, Novadel, and Novartis. She has received research grants from Janssen, Otsuka Pharmaceuticals, and the National Institutes of Health.
--quetiapine (bipolar maintenance) --usu used for schizophrenia
--warfarin (hypertensive heart disease)
--escitalopram (bipolar disorder)
--risperidone (bipolar maintenance)
--montelukast (chronic obstructive pulmonary disease)
--bupropion (bipolar disorder)
--sertraline (bipolar disorder)
--venlafaxine (bipolar disorder)
--celecoxib (fibromatosis)
--lisinopril (coronary artery disease)
--duloxetine (anxiety disorder)
--trazodone (sleep disturbance)
--olanzapine (depression)
--epoetin alfa (anemia of chronic disease)
SOURCES:
http://www.medscape.com/viewarticle/584215?src=mpnews&spon=34&uac=89474MT
(login may be required for medscape, costs nothing)
Pharmacotherapy. 2008;28:1443–1452.
This study was performed by members of the Chicago-Area DEcIDE Center under contract to the Agency for Healthcare Research and Quality (AHRQ) of the US Department of Health and Human Services, Rockville, Maryland. No statement may be construed as the official position of the AHRQ.
Dr. Stafford has received no funding directly relevant to this topic. He has received grant funding from Bayer for research on aspirin use, some of it off-label; Procter and Gamble for bone health research; Toyo Shinyaku for research on an antioxidant dietary supplement; Wako for research testing office-based laboratory equipment; and GlaxoSmithKline for research on calcium supplement use.
Dr. DeVane is a consultant for Janssen Pharmaceuticals, Eli Lilly, Wyeth, Theracos, Novadel, and Novartis. She has received research grants from Janssen, Otsuka Pharmaceuticals, and the National Institutes of Health.
